Immunocore Holdings (IMCR) Short term Debt (2019 - 2024)
Immunocore Holdings (IMCR) posted quarterly Short term Debt of $48.2 million for Q3 2024, up 3787.35% on a QoQ basis from $1.2 million in Q2 2023.
Immunocore Holdings (IMCR) Short term Debt (2019 - 2024) Analysis & Trends
Immunocore Holdings (IMCR) has reported Short term Debt for 3 consecutive years, with $48.2 million the latest figure, recorded in Q3 2024.
- Quarterly Short term Debt changed N/A year-over-year to $48.2 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $48.2 million (changed N/A YoY) and the FY2019 annual result came in at $24.6 million, changed N/A from the prior year.
- Short term Debt advanced to $48.2 million in Q3 2024 per IMCR's latest filing, from $1.2 million in the prior quarter.
- Over the last five years, Short term Debt for IMCR reached as high as $48.2 million in Q3 2024 and fell as low as $1.2 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Immunocore Holdings | 1.80 Bn | 957.43 Mn | 106.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 48.21 Mn |
| Jun 30, 2023 | 1.24 Mn |
| Dec 31, 2019 | 24.63 Mn |